Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year

Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial - The Lancet Neurology

Safety of Mechanical Thrombectomy and Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke. Results of the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) Trial, Part I

Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era

EmpireGene

Hemi Orolingual Angioedema After tPA administration for Acute Ischemic Stroke - The Western Journal of Emergency Medicine

Approach to reperfusion therapy for acute ischemic stroke - UpToDate

JCM, Free Full-Text

Use of tPA for the Management of Acute Ischemic Stroke in the ED: ACEP Policy

Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review - Zhu - 2022 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library

SGEM Xtra: The NNT is Mellow Yellow for tPA in Acute Ischemic Stroke - The Skeptics Guide to Emergency Medicine

Thrombolytics for stroke: The evidence - First10EM

Tissue Plasminogen Activator Market Size, Largest Share Market, Industry Report, 2018-2026, Bayer AG, Abcam, Merck & Company, Roche, Genentech, Sigma-Aldrich, Taj Pharmaceuticals, and Cadila Healthcare Ltd.

Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack